Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

113.60EUR
28 Apr 2017
Change (% chg)

€0.95 (+0.84%)
Prev Close
€112.65
Open
€112.15
Day's High
€114.10
Day's Low
€112.15
Volume
4,493,141
Avg. Vol
1,894,553
52-wk High
€114.10
52-wk Low
€83.45

Latest Key Developments (Source: Significant Developments)

Bayer receives EU approval for new five-year contraceptive
Tuesday, 4 Oct 2016 04:06am EDT 

Bayer AG : Receives green light for new five-year contraceptive in EU Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Bayer and DelSiTech partner to develop drug delivery technology for Ophthalmology
Thursday, 29 Sep 2016 02:30am EDT 

Bayer Ag : Delsitech to receive number of undisclosed milestone payments triggered by successful completion of different stages of development . Bayer and delsitech partner to develop drug delivery technology for ophthalmology .Bayer will fund all development and commercialization costs of collaborative projects.  Full Article

Bayer To start phase III study with Vericiguat
Wednesday, 28 Sep 2016 02:35am EDT 

Bayer AG : Says first patient was enrolled in Victoria, a pivotal phase III clinical study led by Bayer's collaboration partner msd . Says development and commercialization of Vericiguat is part of worldwide strategic collaboration between bayer and msd . Says victoria will enroll approximately 4,900 patients at 530 centres in 39 countries and it is anticipated that study will take 39 months to complet . Says received phase iii approval for vericiguat study . Says event-driven phase iii victoria study will assess efficacy and safety of vericiguat up to 10 mg once daily compared to placebo Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Monsanto India says board to consider Bayer's open offer on Sept 26
Thursday, 22 Sep 2016 05:30am EDT 

Monsanto India Ltd : Meeting on Sept 26 to consider announcement made by Bayer on September 19 regarding open offer Further company coverage: [MNSN.NS] ((ReutersIndia.snapping@thomsonreuters.com;)).  Full Article

Evotec, Bayer to develop new treatments to fight kidney diseases
Wednesday, 21 Sep 2016 01:29am EDT 

Evotec AG : Says goal is development of multiple clinical candidates for treatment of kidney diseases such as chronic kidney disease in diabetes patients . Says partners will share responsibilities during pre-clinical development of potential clinical candidates . Says will receive a minimum of eur 14 m over contract period including research payments and an undisclosed licence fee . Says is eligible to receive pre-clinical, clinical and sales milestones of potentially over eur 300 m as well as tiered royalties of up to low double-digit percentage of net sales .Says evotec and bayer partner to develop new treatments to fight kidney diseases.  Full Article

Bayer & Monsanto seen closing in on deal - CNBC, citing sources
Tuesday, 6 Sep 2016 09:00am EDT 

: Bayer & Monsanto seen closing in on deal; Monsanto told Bayer it is "close" on price- CNBC, citing sources . Bayer, Monsanto deal could happen within a week or two- CNBC, Citing Sources.  Full Article

Monsanto confirms updated proposal from Bayer
Monday, 5 Sep 2016 10:53pm EDT 

: Monsanto confirms updated proposal from Bayer . Monsanto Company - Confirmed it has been engaged in constructive negotiations with Bayer AG . Monsanto Company - Has received an updated non-binding proposal for a potential acquisition of Monsanto for $127.50 per share in cash. .Monsanto Company - Continuing conversations as it evaluates Bayer's proposal, as well as proposals from other parties and other strategic alternatives.  Full Article

Bayer says prepared to offer $127.50 per Monsanto share under an agreement
Monday, 5 Sep 2016 06:41pm EDT 

Bayer : Says confirms advanced negotiations with monsanto concerning a proposed transaction . Bayer says the key conditions of a definitive transaction agreement must be approved by the supervisory board of bayer ag. . Bayer says there can be no assurance that the parties will enter into an agreement .Bayer says while key terms and conditions have not yet been agreed, bayer would be prepared to provide a transaction consideration of usd 127.50 per monsanto share only in connection with a negotiated transaction..  Full Article

Bayer confirms advanced negotiations with Monsanto concerning a proposed transaction
Monday, 5 Sep 2016 06:38pm EDT 

Bayer Ag : Confirms advanced negotiations with Monsanto concerning a proposed transaction . There can be no assurance that the parties will enter into an agreement . Co would be prepared to provide transaction consideration of $127.50 per Monsanto share only in connection with a negotiated transaction .Key terms and conditions have not yet been agreed.  Full Article

Evotec achieves milestone in alliance with Bayer
Thursday, 4 Aug 2016 01:57am EDT 

Evotec Ag : news: evotec achieves clinical development milestone as part of its multi-target alliance with bayer in endometriosis . Says has reached a milestone from bayer for progression of a programme from alliance portfolio into phase i clinical development for treatment of endometriosis, triggering a milestone payment to evotec .Says milestone was achieved under strategic alliance between evotec and bayer entered in october 2012.  Full Article

More From Around the Web

BRIEF-Bayer still sees competition after Monsanto takeover

* Says assumes that there will still be considerable competition even after Monsanto deal is completed Further company coverage: